阿戈美拉汀
单胺类
抗抑郁药
褪黑素
医学
药理学
褪黑激素受体
生物信息学
神经科学
血清素
精神科
心理学
内科学
受体
生物
焦虑
作者
Christian de Bodinat,Béatrice Guardiola‐Lemaître,Elisabeth Mocaër,Pierre Renard,Carmen Muñoz,Mark J. Millan
摘要
Current management of major depression, a common and debilitating disorder with a high social and personal cost, is far from satisfactory. All available antidepressants act through monoaminergic mechanisms, so there is considerable interest in novel non-monoaminergic approaches for potentially improved treatment. One such strategy involves targeting melatonergic receptors, as melatonin has a key role in synchronizing circadian rhythms, which are known to be perturbed in depressed states. This article describes the discovery and development of agomelatine, which possesses both melatonergic agonist and complementary 5-hydroxytryptamine 2C (5-HT2C) antagonist properties. Following comprehensive pharmacological evaluation and extensive clinical trials, agomelatine (Valdoxan/Thymanax; Servier) was granted marketing authorization in 2009 for the treatment of major depression in Europe, thereby becoming the first approved antidepressant to incorporate a non-monoaminergic mechanism of action.
科研通智能强力驱动
Strongly Powered by AbleSci AI